STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S)

Substance: JTE 907

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

- Controlled □
- Not Controlled X

under the schedules of the Controlled Drugs and Substances Act (CDSA) for the following reason(s):

- The substance is a cannabinoid receptor antagonist and is not captured under item 1 of Schedule II to the CDSA.

Prepared by: ____________________________  Date: _________________

Zack Li

Verified by: ____________________________  Date: _________________

Mark Kozlowski

Approved by: ____________________________  Date: _________________

DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES

This status was requested by: “third party information removed as per agreement with applicant”
Drug Status Report

**Drug:** JTE 907

**Drug Name Status:** JTE 907 is the common name.

**Chemical Name:** N-(1,3-Benzodioxol-5-ylmethyl)-1,2-dihydro-7-methoxy-2-oxo-8-(pentyloxy)-3-quinolinecarboxamide

**Other Names:** JTE-907

**Chemical structure:**

![Chemical structure](image)

**Molecular Formula:** $C_{24}H_{26}N_2O_6$

**Pharmacological class / Application:** Synthetic cannabinoid

**CAS-RN:** 282089-49-0

**International status:**

US: JTE 907 is not listed specifically in the Schedules to the US *Controlled Substances Act* and is not mentioned anywhere on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control, the Green List - List of Psychotropic Substances under International Control, nor the Red List - List of Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances under International Control.

Canadian Status: JTE 907 is not listed in the schedules to the CDSA. The substance is a synthetic cannabinoid and in studies evaluating its anti-inflammatory effects, has been found to demonstrate CB$_2$ cannabinoid receptor antagonist activity$^1$. Cannabinoid receptor agonists are currently included under the heading “Cannabis, its preparations, derivatives and similar synthetic preparations” of item 1 in Schedule II to the CDSA, whereas cannabinoid receptor antagonists are specifically excluded. Given that JTE 907 is a cannabinoid receptor antagonist, it cannot be included under item 1 of Schedule II to the CDSA.

---

$^1$Iwamura, H et al. (2001) In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor, J Pharmacol Exp Ther. 296: 420-425
Recommendation:  JTE 907 is not included in the Schedules to the CDSA and is not a controlled substance.

Date:  June 5th, 2012.